CN101951955A - 用于治疗癌症的药物组合物 - Google Patents

用于治疗癌症的药物组合物 Download PDF

Info

Publication number
CN101951955A
CN101951955A CN2008801242034A CN200880124203A CN101951955A CN 101951955 A CN101951955 A CN 101951955A CN 2008801242034 A CN2008801242034 A CN 2008801242034A CN 200880124203 A CN200880124203 A CN 200880124203A CN 101951955 A CN101951955 A CN 101951955A
Authority
CN
China
Prior art keywords
interferon
ifn
cancer
receptor
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801242034A
Other languages
English (en)
Chinese (zh)
Inventor
伊格纳西奥哈维尔·梅莱罗·贝尔梅霍
胡安·杜布罗特·阿门达里斯
桑德拉·埃尔瓦斯·斯塔布斯
阿涅丝洛朗斯·勒邦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Proyecto de Biomedicina CIMA SL
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Proyecto de Biomedicina CIMA SL
Publication of CN101951955A publication Critical patent/CN101951955A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2008801242034A 2007-11-07 2008-11-07 用于治疗癌症的药物组合物 Pending CN101951955A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200702961.P 2007-11-07
ES200702961A ES2336873B1 (es) 2007-11-07 2007-11-07 Composicion farmaceutica para el tratamiento de cancer.
PCT/ES2008/000693 WO2009060112A1 (es) 2007-11-07 2008-11-07 Composición farmacéutica para el tratamiento de cáncer

Publications (1)

Publication Number Publication Date
CN101951955A true CN101951955A (zh) 2011-01-19

Family

ID=40351964

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801242034A Pending CN101951955A (zh) 2007-11-07 2008-11-07 用于治疗癌症的药物组合物

Country Status (11)

Country Link
US (1) US20110059045A1 (enExample)
EP (1) EP2223701A1 (enExample)
JP (1) JP2011503039A (enExample)
CN (1) CN101951955A (enExample)
AU (1) AU2008324056A1 (enExample)
BR (1) BRPI0820351A2 (enExample)
CA (1) CA2705105A1 (enExample)
ES (1) ES2336873B1 (enExample)
MX (1) MX2010005086A (enExample)
RU (1) RU2010122934A (enExample)
WO (1) WO2009060112A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114751989A (zh) * 2015-03-31 2022-07-15 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9789202B2 (en) 2011-09-05 2017-10-17 Hanmi Science Co., Ltd. Method for treating cancer using an interferon alpha conjugate
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
TWI718086B (zh) * 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
EP3082839A4 (en) * 2013-12-20 2017-08-09 National University of Singapore Differentiation therapy with cd137 ligand agonists
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
WO2006088447A1 (en) * 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
KR20080068089A (ko) * 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114751989A (zh) * 2015-03-31 2022-07-15 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子
US12202870B2 (en) 2015-03-31 2025-01-21 Hoffmann-La Roche Inc. Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof

Also Published As

Publication number Publication date
AU2008324056A1 (en) 2009-05-14
ES2336873A1 (es) 2010-04-16
JP2011503039A (ja) 2011-01-27
BRPI0820351A2 (pt) 2015-10-27
WO2009060112A1 (es) 2009-05-14
CA2705105A1 (en) 2009-05-14
EP2223701A1 (en) 2010-09-01
ES2336873B1 (es) 2011-01-24
MX2010005086A (es) 2010-08-10
US20110059045A1 (en) 2011-03-10
RU2010122934A (ru) 2011-12-20

Similar Documents

Publication Publication Date Title
RU2711979C2 (ru) Белковый комплекс интерлейкина 15 и его применение
CN101951955A (zh) 用于治疗癌症的药物组合物
US9844582B2 (en) Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
JP4494977B2 (ja) Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
US12466868B2 (en) Engineered proteins to enhance sensitivity of a cell to IL-2
CN107223135B (zh) 用于治疗hbv感染和相关病症的三特异性结合分子
CN105189562B (zh) Il-15异源二聚体蛋白及其用途
CN108129573B (zh) 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
KR100909290B1 (ko) 항암 항체
US12497447B2 (en) Anti-GDF15 antibody and a dosage regimen for the treatment of cancer
CN113728005A (zh) Cd3特异性结合分子
CN116322785A (zh) 包含il-10的双细胞因子融合蛋白
CN117304342A (zh) 嵌合抗原受体及其应用
EP1256354A1 (en) Methods for treating cancer
CN114053403A (zh) 融合蛋白在制备疫苗佐剂或预防和治疗病毒感染的药物中的用途
CN116419970B (zh) 低毒性抗ox40抗体、其药物组合物及应用
JP2025534020A (ja) 治療的抗体薬物における抗体の突然変異方法の使用
WO2025119304A1 (en) Heterodimeric proteins against il-12 receptor
CN119192389B (zh) 双特异性抗体及其应用
CN120818060A (zh) Lilrb4-cd3双特异性抗体及其应用
Nadal Isolation and validation of novel monoclonal antibodies targeting the tumor microenvironment for the selective delivery of cytokines payloads
JP2025532554A (ja) Ｉｌ－２スーパーアンタゴニストコンストラクト、方法、及びそれらの使用
CN120718155A (zh) Psma-cd3的双特异性抗体及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110119